Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07130903 · ClinicalTrials.gov registry record · Phase 2
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Adenocarcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 9
- Study locations
NCT07130903 is a Phase 2 study of Metastatic Colorectal Adenocarcinoma that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 102 participants, above the 81-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (26% higher). The trial reports 9 study locations across 1 state.
The verdict
NCT07130903, a Phase 2 study of Metastatic Colorectal Adenocarcinoma, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
Conditions Studied
Interventions
- DRUG Fruquintinib
- DEVICE TheraBionic P1
Study Locations (9)
Michigan
- Karmanos Cancer Institute at McLaren Bay Region - Bay City
- Karmanos Cancer Institute at McLaren Clarkston - Clarkston
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute at McLaren Flint - Flint
- Karmanos Cancer Institute at McLaren Greater Lansing - Lansing
- Karmanos Cancer Institute at McLaren Lapeer Region - Lapeer
- Karmanos Cancer Institute at McLaren Macomb - Macomb
- Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey - Petoskey
- Karmanos Cancer Institute at McLaren Port Huron - Port Huron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2030-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07130903
The ClinicalTrials.gov registry entry for NCT07130903 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (26% higher). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Fruquintinib is the first listed.
NCT07130903 reports 9 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07130903 about?
NCT07130903 is a clinical study titled "Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer". The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
What is the current status of trial NCT07130903?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2025-09-10. Estimated completion is 2030-04-17.
What conditions does trial NCT07130903 study?
This clinical trial studies the following conditions: Metastatic Colorectal Adenocarcinoma.
What interventions are being tested in trial NCT07130903?
The interventions under investigation include: Fruquintinib (DRUG), TheraBionic P1 (DEVICE).
Who is sponsoring clinical trial NCT07130903?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07130903 being conducted?
This trial has 9 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
COMPLETED · Phase 2
-
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
RECRUITING · Phase 1
-
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.